Xiangjun Qi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiangjun Qi has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Guoming Chen
School of Chinese Medicine
5 shared publications- Caishan Fang
Chengdu University of Traditional Chinese Medicine
3 shared publications - Lizhu Lin
The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
3 shared publications Caishan Fang
The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou 510405, China
2 shared publicationsJietao Lin
The First Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou China
2 shared publications- Jietao Lin
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
2 shared publications
Latest Publications
- Open Access
- 15 July 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e78534
Clinical Study on the Prevention of High-Risk Pulmonary Nodule Progression With Yifei Sanjie Pill: Protocol for a Multicenter Randomized Controlled Trial.
High-risk subsolid pulmonary nodules, especially mixed ground-glass nodules, can represent precancerous or early-stage lung adenocarcinoma spectrum lesions. Standard management relies mainly on risk stratification, repeated thin-slice computed tomography, and invasive diagnosis or surgery when progression suggests malignancy. Safe adjunctive pharmacologic options to reduce nodule progression remain limited. Yifei Sanjie Pill (YFSJ) is an 8-herb traditional Chinese medicine formula that has been previously studied as an adjunctive treatment for non-small cell lung cancer. However, its effect on high-risk pulmonary nodules-a distinct clinical condition-has not yet been investigated. This protocol describes a multicenter randomized trial evaluating the efficacy, safety, and exploratory mechanisms of YFSJ for preventing high-risk pulmonary nodule progression. Adults aged 18 to 80 years with single or multiple mixed ground-glass nodules measuring ≤8 mm will be randomized in a 1:1 ratio to receive YFSJ optimized formula granules or matched placebo granules, 2 packets twice daily for 6 months. Both groups will receive guideline-based computed tomography surveillance and any clinically indicated standard diagnostic or therapeutic care. The primary outcome is the 2-year pulmonary nodule progression rate, defined as an increase in the lesion's longest diameter of ≥2 mm, an increase in the solid component of ≥1 mm, or the appearance of a new solid component. Secondary outcomes include lung cancer detection rate, surgery rate, 6-month nodule size and volume change, artificial intelligence-based malignancy risk index, traditional Chinese medicine symptom score, Hospital Anxiety and Depression Scale (HADS) score, Pittsburgh Sleep Quality Index (PSQI) score, safety indicators, and exploratory plasma biomarkers. The primary analysis will use the full analysis set, Kaplan-Meier estimates, log-rank testing, and Cox regression adjusted for center and key covariates; repeated outcomes will be analyzed using mixed-effects models. The study was funded in 2022 and approved by the Research Ethics Committee of the First Affiliated Hospital of Guangzhou University of Chinese Medicine (K-2022-131-XZ-01). Recruitment started in June 2023 and was scheduled for completion in December 2025. As of April 2026, a total of 589 participants have completed randomization. The final 2-year follow-up is scheduled for December 2027. Database lock and primary analysis are planned for early 2028, and submission of the first results is expected in spring or summer 2028. This trial will determine whether adding YFSJ to guideline-based surveillance can reduce high-risk pulmonary nodule progression and provide mechanistic evidence for integrative early lung cancer prevention.
- 15 July 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e78534
Open AccessClinical Study on the Prevention of High-Risk Pulmonary Nodule Progression With Yifei Sanjie Pill: Protocol for a Multicenter Randomized Controlled Trial.
High-risk subsolid pulmonary nodules, especially mixed ground-glass nodules, can represent precancerous or early-stage lung adenocarcinoma spectrum lesions. Standard management relies mainly on risk stratification, repeated thin-slice computed tomography, and invasive diagnosis or surgery when progression suggests malignancy. Safe adjunctive pharmacologic options to reduce nodule progression remain limited. Yifei Sanjie Pill (YFSJ) is an 8-herb traditional Chinese medicine formula that has been previously studied as an adjunctive treatment for non-small cell lung cancer. However, its effect on high-risk pulmonary nodules-a distinct clinical condition-has not yet been investigated. This protocol describes a multicenter randomized trial evaluating the efficacy, safety, and exploratory mechanisms of YFSJ for preventing high-risk pulmonary nodule progression. Adults aged 18 to 80 years with single or multiple mixed ground-glass nodules measuring ≤8 mm will be randomized in a 1:1 ratio to receive YFSJ optimized formula granules or matched placebo granules, 2 packets twice daily for 6 months. Both groups will receive guideline-based computed tomography surveillance and any clinically indicated standard diagnostic or therapeutic care. The primary outcome is the 2-year pulmonary nodule progression rate, defined as an increase in the lesion's longest diameter of ≥2 mm, an increase in the solid component of ≥1 mm, or the appearance of a new solid component. Secondary outcomes include lung cancer detection rate, surgery rate, 6-month nodule size and volume change, artificial intelligence-based malignancy risk index, traditional Chinese medicine symptom score, Hospital Anxiety and Depression Scale (HADS) score, Pittsburgh Sleep Quality Index (PSQI) score, safety indicators, and exploratory plasma biomarkers. The primary analysis will use the full analysis set, Kaplan-Meier estimates, log-rank testing, and Cox regression adjusted for center and key covariates; repeated outcomes will be analyzed using mixed-effects models. The study was funded in 2022 and approved by the Research Ethics Committee of the First Affiliated Hospital of Guangzhou University of Chinese Medicine (K-2022-131-XZ-01). Recruitment started in June 2023 and was scheduled for completion in December 2025. As of April 2026, a total of 589 participants have completed randomization. The final 2-year follow-up is scheduled for December 2027. Database lock and primary analysis are planned for early 2028, and submission of the first results is expected in spring or summer 2028. This trial will determine whether adding YFSJ to guideline-based surveillance can reduce high-risk pulmonary nodule progression and provide mechanistic evidence for integrative early lung cancer prevention.
- 8 January 2026
- Published by Wiley in Phytotherapy Research
- Vol. 40 (2) , 800-811
Chlorogenic Acid Regulates Macrophage Polarization in LUAD by Inhibiting Taurodeoxycholic Acid Metabolism to Block the TGR5 / STAT3 Signaling Pathway
Lung adenocarcinoma (LUAD) poses a leading cause of cancer‐related mortality, necessitating the need for effective and less toxic therapies. Chlorogenic Acid (CGA), a naturally occurring polyphenol, has attracted attention for its potential anti‐tumor properties, but its efficacy and mechanisms in LUAD require thorough investigation. To evaluate CGA's potential, we conducted a comprehensive study in a LUAD mouse model. We performed CT scanning and histopathological analysis to confirm its dose‐dependent inhibition of tumor growth. Body weight monitoring assessed its lower systemic toxicity compared to cisplatin. Flow cytometry revealed CGA's unique ability to reprogram tumor‐associated macrophages by reducing immunosuppressive M2 polarization and promoting anti‐tumor M1 phenotypes. Metabolomic profiling identified a significant reduction in the pro‐tumor metabolite taurodeoxycholic acid (TDCA) upon CGA treatment. Subsequent in vitro co‐culture studies and western blot analysis demonstrated that CGA disrupts the TDCA‐activated TGR5/STAT3 signaling axis, which is crucial for M2 macrophage polarization. Our findings unveil a novel immunometabolic mechanism through which CGA suppresses LUAD by remodeling the tumor microenvironment, highlighting its promise as a therapeutic agent or adjunct with both efficacy and a favorable safety profile.
- 8 January 2026
- Published by Wiley in Phytotherapy Research
- Vol. 40 (2) , 800-811
Chlorogenic Acid Regulates Macrophage Polarization in LUAD by Inhibiting Taurodeoxycholic Acid Metabolism to Block the TGR5 / STAT3 Signaling Pathway
Lung adenocarcinoma (LUAD) poses a leading cause of cancer‐related mortality, necessitating the need for effective and less toxic therapies. Chlorogenic Acid (CGA), a naturally occurring polyphenol, has attracted attention for its potential anti‐tumor properties, but its efficacy and mechanisms in LUAD require thorough investigation. To evaluate CGA's potential, we conducted a comprehensive study in a LUAD mouse model. We performed CT scanning and histopathological analysis to confirm its dose‐dependent inhibition of tumor growth. Body weight monitoring assessed its lower systemic toxicity compared to cisplatin. Flow cytometry revealed CGA's unique ability to reprogram tumor‐associated macrophages by reducing immunosuppressive M2 polarization and promoting anti‐tumor M1 phenotypes. Metabolomic profiling identified a significant reduction in the pro‐tumor metabolite taurodeoxycholic acid (TDCA) upon CGA treatment. Subsequent in vitro co‐culture studies and western blot analysis demonstrated that CGA disrupts the TDCA‐activated TGR5/STAT3 signaling axis, which is crucial for M2 macrophage polarization. Our findings unveil a novel immunometabolic mechanism through which CGA suppresses LUAD by remodeling the tumor microenvironment, highlighting its promise as a therapeutic agent or adjunct with both efficacy and a favorable safety profile.
- 18 December 2025
- Published by SAGE Publications in American Journal of Rhinology & Allergy
- Vol. 40 (3) , 197-206
Association Between Exposure to Phenols and Parabens and Allergy-Related Outcomes
Background: Parabens and phenols (PAPs) are widely used in consumer and personal care products. Although prior studies suggest links between PAP exposure and allergic outcomes, evidence across adolescents and adults remains limited. Objective: To investigate associations between urinary PAPs and allergy-related outcomes. Methods: We conducted a cross-sectional analysis of NHANES 2005-2006. Eight urinary PAPs were considered; three with >33.3% values below the limit of detection were excluded. Allergic symptoms and sensitization were assessed based on participants’ self-reported health conditions. Three survey-weighted generalized linear models (crude model: unadjusted; Model I: partially adjusted; Model II: fully adjusted) and weighted quantile sum regression were used to evaluate the associations between PAPs exposure and allergy-related outcomes in both adolescents and adults. Results: Among adolescents, higher triclosan (TCS) exposure was positively associated with allergic rhinitis, allergies, sinus infection, and sneezing; in the fully adjusted model, odds ratios (ORs) were 2.04 (95% CI: 1.18-3.54), 2.36 (1.25-4.47), 3.28 (1.36-7.91), and 2.12 (1.27-3.52), respectively. Higher TCS, methyl paraben (MPB), and propyl paraben (PPB) were associated with dust-mite sensitization, with ORs of 2.00 (1.16-3.45), 2.09 (1.05-4.17), and 3.87 (2.09-7.16). Among adults, MPB was positively associated with allergic rhinitis (OR = 1.95, 95% CI: 1.26-3.00) and sneezing (OR = 1.99, 1.27-3.10), and TCS was associated with hay fever (OR = 1.99, 1.22-3.23) and plant sensitization (OR = 1.40, 1.03-1.91). In mixture analyses, PAPs were positively associated with allergies (adjusted OR = 1.27, 95% CI: 1.07-1.51), sneezing (1.15, 1.00-1.33), and plant sensitization (1.21, 1.02-1.43) in adolescents, but no significant mixture associations were found in adults. Conclusion: Higher levels of specific PAPs, particularly TCS, MPB, and PPB, and PAP mixtures were associated with increased risks of allergy-related outcomes in adolescents. In adults, TCS and MPB showed positive associations with multiple outcomes, whereas the overall PAP mixture was not statistically significant.
- 18 December 2025
- Published by SAGE Publications in American Journal of Rhinology & Allergy
- Vol. 40 (3) , 197-206
Association Between Exposure to Phenols and Parabens and Allergy-Related Outcomes
Background: Parabens and phenols (PAPs) are widely used in consumer and personal care products. Although prior studies suggest links between PAP exposure and allergic outcomes, evidence across adolescents and adults remains limited. Objective: To investigate associations between urinary PAPs and allergy-related outcomes. Methods: We conducted a cross-sectional analysis of NHANES 2005-2006. Eight urinary PAPs were considered; three with >33.3% values below the limit of detection were excluded. Allergic symptoms and sensitization were assessed based on participants’ self-reported health conditions. Three survey-weighted generalized linear models (crude model: unadjusted; Model I: partially adjusted; Model II: fully adjusted) and weighted quantile sum regression were used to evaluate the associations between PAPs exposure and allergy-related outcomes in both adolescents and adults. Results: Among adolescents, higher triclosan (TCS) exposure was positively associated with allergic rhinitis, allergies, sinus infection, and sneezing; in the fully adjusted model, odds ratios (ORs) were 2.04 (95% CI: 1.18-3.54), 2.36 (1.25-4.47), 3.28 (1.36-7.91), and 2.12 (1.27-3.52), respectively. Higher TCS, methyl paraben (MPB), and propyl paraben (PPB) were associated with dust-mite sensitization, with ORs of 2.00 (1.16-3.45), 2.09 (1.05-4.17), and 3.87 (2.09-7.16). Among adults, MPB was positively associated with allergic rhinitis (OR = 1.95, 95% CI: 1.26-3.00) and sneezing (OR = 1.99, 1.27-3.10), and TCS was associated with hay fever (OR = 1.99, 1.22-3.23) and plant sensitization (OR = 1.40, 1.03-1.91). In mixture analyses, PAPs were positively associated with allergies (adjusted OR = 1.27, 95% CI: 1.07-1.51), sneezing (1.15, 1.00-1.33), and plant sensitization (1.21, 1.02-1.43) in adolescents, but no significant mixture associations were found in adults. Conclusion: Higher levels of specific PAPs, particularly TCS, MPB, and PPB, and PAP mixtures were associated with increased risks of allergy-related outcomes in adolescents. In adults, TCS and MPB showed positive associations with multiple outcomes, whereas the overall PAP mixture was not statistically significant.
- Open Access
- 29 January 2023
- Published by SAGE Publications in Integrative Cancer Therapies
- Vol. 22
Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study
Background: Anlotinib is used as a third-line treatment for advanced non-small-cell lung cancer (NSCLC), but has limited clinical benefits and several side effects, such as diarrhea and acneiform skin rash. Traditional Chinese Medicine (TCM) is commonly used to treat cancers in China. Chinese herbal medicines may have the potential as adjuvant therapies to reduce toxicity and improve the efficacy of treatments for NSCLC. Given the positive outcomes of basic research, we plan to evaluate whether the addition of the Chinese herbal medicine Yifei Sanjie formula (YFSJF) to anlotinib can improve the progression-free survival (PFS) of advanced NSCLC patients. Methods: A multicenter, randomized, double-blind, placebo-controlled parallel-group controlled pilot trial will be performed. Forty eligible patients will be randomized in a ratio of 1:1 to the intervention (YFSJF + anlotinib) and control (placebo + anlotinib) groups. Participants will be advised to take 12 mg/day of anlotinib on days 1 to 14 of each 21-day cycle. YFSJF or placebo will be administered (15 g twice daily) during each cycle until progression of disease (PD). The primary outcome will be progression-free survival (PFS), and the secondary outcomes will be overall survival (OS), the objective response rate (ORR), and patient-reported outcomes (PRO). Tumors will be assessed based on RECIST v. 1.1 after every 2 cycles of treatment. The M. D. Anderson Symptom Inventory-Lung Cancer (MDASI-LC) will be used to evaluate PRO at baseline and weekly thereafter until PD. Discussion: This will be the first trial to evaluate the effectiveness and safety of TCM combined with anlotinib for the treatment of NSCLC. The results of this randomized controlled trial will fill a gap in the research by showing whether YFSJF combined with anlotinib can improve PFS in NSCLC patients. Trial Registration: The study was registered on June 8th, 2021 on Chinese Clinical Registry; registration number ChiCTR2100047143. ( https://www.chictr.org.cn/index.aspx ). Ethics and Dissemination: The Ethics Committee of the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine approved the study protocol (approval no.: K2020151, 2021/08/19). The study will also be supervised and managed by the Ethics Committee.
- 29 January 2023
- Published by SAGE Publications in Integrative Cancer Therapies
- Vol. 22
Open AccessYifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study
Background: Anlotinib is used as a third-line treatment for advanced non-small-cell lung cancer (NSCLC), but has limited clinical benefits and several side effects, such as diarrhea and acneiform skin rash. Traditional Chinese Medicine (TCM) is commonly used to treat cancers in China. Chinese herbal medicines may have the potential as adjuvant therapies to reduce toxicity and improve the efficacy of treatments for NSCLC. Given the positive outcomes of basic research, we plan to evaluate whether the addition of the Chinese herbal medicine Yifei Sanjie formula (YFSJF) to anlotinib can improve the progression-free survival (PFS) of advanced NSCLC patients. Methods: A multicenter, randomized, double-blind, placebo-controlled parallel-group controlled pilot trial will be performed. Forty eligible patients will be randomized in a ratio of 1:1 to the intervention (YFSJF + anlotinib) and control (placebo + anlotinib) groups. Participants will be advised to take 12 mg/day of anlotinib on days 1 to 14 of each 21-day cycle. YFSJF or placebo will be administered (15 g twice daily) during each cycle until progression of disease (PD). The primary outcome will be progression-free survival (PFS), and the secondary outcomes will be overall survival (OS), the objective response rate (ORR), and patient-reported outcomes (PRO). Tumors will be assessed based on RECIST v. 1.1 after every 2 cycles of treatment. The M. D. Anderson Symptom Inventory-Lung Cancer (MDASI-LC) will be used to evaluate PRO at baseline and weekly thereafter until PD. Discussion: This will be the first trial to evaluate the effectiveness and safety of TCM combined with anlotinib for the treatment of NSCLC. The results of this randomized controlled trial will fill a gap in the research by showing whether YFSJF combined with anlotinib can improve PFS in NSCLC patients. Trial Registration: The study was registered on June 8th, 2021 on Chinese Clinical Registry; registration number ChiCTR2100047143. ( https://www.chictr.org.cn/index.aspx ). Ethics and Dissemination: The Ethics Committee of the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine approved the study protocol (approval no.: K2020151, 2021/08/19). The study will also be supervised and managed by the Ethics Committee.
- Open Access
- 15 December 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1010131
Impairment mechanism of nasal mucosa after radiotherapy for nasopharyngeal carcinoma
The nasal mucosa, which performs the crucial functions of filtering, humidifying and temperature regulation, is one of the most vulnerable areas of nasopharyngeal carcinoma (NPC) patients after radiotherapy (RT). Following RT, NPC patients experience a series of pathological changes in the nasal mucosa, ultimately leading to physiological dysfunction of the nasal epithelium. This article systematically reviews the clinical and pathological manifestations of RT-related nasal damage in NPC patients and summarizes the potential mechanism of damage to the human nasal epithelium by RT. Finally, we outline the current mechanistic models of nasal epithelial alterations after RT in NPC patients and provide additional information to extend the in-depth study on the impairment mechanisms of the nasal mucosa resulting from RT. We also describe the relationship between structural and functional alterations in the nasal mucosa after RT to help mitigate and treat this damage and provide insights informing future clinical and fundamental investigations.
- 15 December 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1010131
Open AccessImpairment mechanism of nasal mucosa after radiotherapy for nasopharyngeal carcinoma
The nasal mucosa, which performs the crucial functions of filtering, humidifying and temperature regulation, is one of the most vulnerable areas of nasopharyngeal carcinoma (NPC) patients after radiotherapy (RT). Following RT, NPC patients experience a series of pathological changes in the nasal mucosa, ultimately leading to physiological dysfunction of the nasal epithelium. This article systematically reviews the clinical and pathological manifestations of RT-related nasal damage in NPC patients and summarizes the potential mechanism of damage to the human nasal epithelium by RT. Finally, we outline the current mechanistic models of nasal epithelial alterations after RT in NPC patients and provide additional information to extend the in-depth study on the impairment mechanisms of the nasal mucosa resulting from RT. We also describe the relationship between structural and functional alterations in the nasal mucosa after RT to help mitigate and treat this damage and provide insights informing future clinical and fundamental investigations.
- Open Access
- 16 November 2022
- Published by Wiley in Journal of Immunology Research
- Vol. 2022, 1-32
Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma
Background. Copper (Cu) metabolism is strongly associated with liver disease. Cuproptosis is a novel format of cell death, and cuproptosis-related genes (CRGs) were identified. However, the role of CRGs in Hepatocellular Carcinoma (HCC) remains unknown. Method. The mRNA transcriptome profiling data, somatic mutation data, and copy number gene level data of The Cancer Genome Atlas-Liver Hepatocellular Carcinoma project (TCGA-LIHC) were downloaded for subsequent analysis. Molecular characterization analysis of CRGs, including differential gene expression analysis, mutation analysis, copy number variation (CNV) analysis, Kaplan-Meier analysis, and immune regulator prioritization analysis, was implemented. The nonnegative matrix factorization (NMF) approach was used to identify the CRG-related molecular subtypes. Principal component analysis was adopted to verify the robustness and reliability of the molecular subtype. The least absolute shrinkage and selection operator regression analysis was performed to construct the prognostic signature based on differentially expressed genes between molecular subtypes. The survival characteristics of the molecular subtype and the signature were analyzed. The Gene Set Variation Analysis was performed for functional annotation. The immune landscape analysis, including immune checkpoint gene analysis, single sample gene set enrichment analysis, tumor immune dysfunction and exclusion (TIDE) analysis, immune infiltration cell, and tumor mutation burden analysis (TMB), was conducted. The ability of the signature to predict conventional anti-HCC agent responses was evaluated. The signature was validated in the LIRI-JP cohort and the IMvigor210 cohort. Result. A total of 13 CRGs are differentially expressed between the tumor and normal samples, while the mutation of CRGs in HCC is infrequent. The expression of CRGs is associated with the CNV level. Fourteen CRGs are associated with the prognosis of HCC. Two clusters were identified and HCC patients were divided into 2 groups with a cutoff risk score value of 1.570. HCC patients in the C1 cluster and high-risk have a worse prognosis. The area under the receiver operating characteristic curve for predicting 1-, 2-, and 3-year overall survival is 0.775, 0.768, and 0.757 in the TCGA-LIHC cohort, and 0.811, 0.741, and 0.775 in the LIRI-JP cohort. Multivariate Cox regression analysis indicates that the signature is an independent prognostic factor. Pathways involved in metabolism and gene stability and immune infiltration cells are significantly enriched. Immune checkpoint genes are highly expressed in the C1 cluster. TMB is positively correlated with the risk score. HCC patients in the high-risk group are more likely to benefit from conventional anti-HCC agents and immune checkpoint inhibitor therapies. Conclusion. The molecular characterization of CRGs in HCC is presented in this study, and a successful prognostic signature for HCC based on the cuproptosis-related molecular subtype was constructed.
- 16 November 2022
- Published by Wiley in Journal of Immunology Research
- Vol. 2022, 1-32
Open AccessCuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma
Background. Copper (Cu) metabolism is strongly associated with liver disease. Cuproptosis is a novel format of cell death, and cuproptosis-related genes (CRGs) were identified. However, the role of CRGs in Hepatocellular Carcinoma (HCC) remains unknown. Method. The mRNA transcriptome profiling data, somatic mutation data, and copy number gene level data of The Cancer Genome Atlas-Liver Hepatocellular Carcinoma project (TCGA-LIHC) were downloaded for subsequent analysis. Molecular characterization analysis of CRGs, including differential gene expression analysis, mutation analysis, copy number variation (CNV) analysis, Kaplan-Meier analysis, and immune regulator prioritization analysis, was implemented. The nonnegative matrix factorization (NMF) approach was used to identify the CRG-related molecular subtypes. Principal component analysis was adopted to verify the robustness and reliability of the molecular subtype. The least absolute shrinkage and selection operator regression analysis was performed to construct the prognostic signature based on differentially expressed genes between molecular subtypes. The survival characteristics of the molecular subtype and the signature were analyzed. The Gene Set Variation Analysis was performed for functional annotation. The immune landscape analysis, including immune checkpoint gene analysis, single sample gene set enrichment analysis, tumor immune dysfunction and exclusion (TIDE) analysis, immune infiltration cell, and tumor mutation burden analysis (TMB), was conducted. The ability of the signature to predict conventional anti-HCC agent responses was evaluated. The signature was validated in the LIRI-JP cohort and the IMvigor210 cohort. Result. A total of 13 CRGs are differentially expressed between the tumor and normal samples, while the mutation of CRGs in HCC is infrequent. The expression of CRGs is associated with the CNV level. Fourteen CRGs are associated with the prognosis of HCC. Two clusters were identified and HCC patients were divided into 2 groups with a cutoff risk score value of 1.570. HCC patients in the C1 cluster and high-risk have a worse prognosis. The area under the receiver operating characteristic curve for predicting 1-, 2-, and 3-year overall survival is 0.775, 0.768, and 0.757 in the TCGA-LIHC cohort, and 0.811, 0.741, and 0.775 in the LIRI-JP cohort. Multivariate Cox regression analysis indicates that the signature is an independent prognostic factor. Pathways involved in metabolism and gene stability and immune infiltration cells are significantly enriched. Immune checkpoint genes are highly expressed in the C1 cluster. TMB is positively correlated with the risk score. HCC patients in the high-risk group are more likely to benefit from conventional anti-HCC agents and immune checkpoint inhibitor therapies. Conclusion. The molecular characterization of CRGs in HCC is presented in this study, and a successful prognostic signature for HCC based on the cuproptosis-related molecular subtype was constructed.
- Open Access
- 2 August 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-18
Investigating the Mechanism of Scutellariae barbata Herba in the Treatment of Colorectal Cancer by Network Pharmacology and Molecular Docking
Background. Colorectal cancer (CRC) is one of the most common gastrointestinal tumors, which accounts for approximately 10 of all diagnosed cancers and cancer deaths worldwide per year. Scutellariae barbatae Herba (SBH) is one of the most frequently used traditional Chinese medicine (TCM) in the treatment of CRC. Although many experiments have been carried out to explain the mechanisms of SBH, the mechanisms of SBH have not been illuminated fully. Thus, we constructed a network pharmacology and molecular docking to investigate the mechanisms of SBH. Methods. We adopted active constituent prescreening, target predicting, protein-protein interaction (PPI) analysis, Gene Ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, differentially expressed gene analysis, and molecular docking to establish a system pharmacology database of SBH against CRC. Results. A total of 64 active constituents of SBH were obtained and 377 targets were predicted, and the result indicated that quercetin, luteolin, wogonin, and apigenin were the main active constituents of SBH. Glucocorticoid receptor (NR3C1), pPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA), cellular tumor antigen p53 (TP53), transcription factor AP-1 (JUN), mitogen-activated protein kinase 1 (MAPK1), Myc protooncogene protein (MYC), cyclin-dependent kinase 1 (CDK1), and broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) were the major targets of SBH in the treatment of CRC. GO analysis illustrated that the core biological process regulated by SBH was the regulation of the cell cycle. Thirty pathways were presented and 8 pathways related to CRC were involved. Molecular docking presented the binding details of 3 key targets with 6 active constituents. Conclusions. The mechanisms of SBH against CRC depend on the synergistic effect of multiple active constituents, multiple targets, and multiple pathways.
- 2 August 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-18
Open AccessInvestigating the Mechanism of Scutellariae barbata Herba in the Treatment of Colorectal Cancer by Network Pharmacology and Molecular Docking
Background. Colorectal cancer (CRC) is one of the most common gastrointestinal tumors, which accounts for approximately 10 of all diagnosed cancers and cancer deaths worldwide per year. Scutellariae barbatae Herba (SBH) is one of the most frequently used traditional Chinese medicine (TCM) in the treatment of CRC. Although many experiments have been carried out to explain the mechanisms of SBH, the mechanisms of SBH have not been illuminated fully. Thus, we constructed a network pharmacology and molecular docking to investigate the mechanisms of SBH. Methods. We adopted active constituent prescreening, target predicting, protein-protein interaction (PPI) analysis, Gene Ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, differentially expressed gene analysis, and molecular docking to establish a system pharmacology database of SBH against CRC. Results. A total of 64 active constituents of SBH were obtained and 377 targets were predicted, and the result indicated that quercetin, luteolin, wogonin, and apigenin were the main active constituents of SBH. Glucocorticoid receptor (NR3C1), pPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA), cellular tumor antigen p53 (TP53), transcription factor AP-1 (JUN), mitogen-activated protein kinase 1 (MAPK1), Myc protooncogene protein (MYC), cyclin-dependent kinase 1 (CDK1), and broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) were the major targets of SBH in the treatment of CRC. GO analysis illustrated that the core biological process regulated by SBH was the regulation of the cell cycle. Thirty pathways were presented and 8 pathways related to CRC were involved. Molecular docking presented the binding details of 3 key targets with 6 active constituents. Conclusions. The mechanisms of SBH against CRC depend on the synergistic effect of multiple active constituents, multiple targets, and multiple pathways.
- Open Access
- 1 August 2021
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 14, 4279-4289
Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature
Background: A growing number of studies have demonstrated that immune-related long noncoding ribonucleic acids (irlncRNAs) are potential prognostic factors for lung adenocarcinoma. Two-gene combination patterns could improve the sensitivity of prognostic models, providing us a novel signature construction concept that we applied to lung adenocarcinoma. Methods: Gene expression and clinical data were downloaded from the Lung Adenocarcinoma project of The Cancer Genome Atlas (TCGA) database. We applied a co-expression analysis with immune genes obtained from the ImmPort database to recognize irlncRNA. The matrix of irlncRNA pairs was established by a cyclic comparison of each lncRNA pair expression level. Univariate and multivariate Cox regressions and Lasso penalized regression analysis were applied to construct the risk model. Patients with lung adenocarcinoma were divided into high- and low-risk groups, according to the Akaike Information Criterion (AIC) values of the receiver operating characteristic (ROC) curve. Then, we evaluated our signature under various clinical settings: clinical-pathological characteristics, tumor-infiltrating immune cells, checkpoint-related biomarkers, targeted therapy, and chemotherapy. Results: Based on the 239 differently expressed irlncRNAs, we constructed an 11-irlncRNA pair signature. The area under the curve (AUC) of the ROC curve for the signature to predict the 4-year survival rate was 0.819, and the cut-off point was recognized as 1.003. Subsequent analysis showed that our signature can effectively distinguish unfavorable survival outcomes, prognostic clinic-pathological characteristics, and specify tumor infiltration status. Highly expressed immune checkpoint-related genes, as well as higher chemosensitivity, were correlated to the low-risk group. Conclusion: We constructed a novel lung adenocarcinoma irlncRNA signature with promising prognostic value using the TCGA database, based on paired irlncRNAs and not relying on lncRNAs special expression levels.
- 1 August 2021
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 14, 4279-4289
Open AccessConstruction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature
Background: A growing number of studies have demonstrated that immune-related long noncoding ribonucleic acids (irlncRNAs) are potential prognostic factors for lung adenocarcinoma. Two-gene combination patterns could improve the sensitivity of prognostic models, providing us a novel signature construction concept that we applied to lung adenocarcinoma. Methods: Gene expression and clinical data were downloaded from the Lung Adenocarcinoma project of The Cancer Genome Atlas (TCGA) database. We applied a co-expression analysis with immune genes obtained from the ImmPort database to recognize irlncRNA. The matrix of irlncRNA pairs was established by a cyclic comparison of each lncRNA pair expression level. Univariate and multivariate Cox regressions and Lasso penalized regression analysis were applied to construct the risk model. Patients with lung adenocarcinoma were divided into high- and low-risk groups, according to the Akaike Information Criterion (AIC) values of the receiver operating characteristic (ROC) curve. Then, we evaluated our signature under various clinical settings: clinical-pathological characteristics, tumor-infiltrating immune cells, checkpoint-related biomarkers, targeted therapy, and chemotherapy. Results: Based on the 239 differently expressed irlncRNAs, we constructed an 11-irlncRNA pair signature. The area under the curve (AUC) of the ROC curve for the signature to predict the 4-year survival rate was 0.819, and the cut-off point was recognized as 1.003. Subsequent analysis showed that our signature can effectively distinguish unfavorable survival outcomes, prognostic clinic-pathological characteristics, and specify tumor infiltration status. Highly expressed immune checkpoint-related genes, as well as higher chemosensitivity, were correlated to the low-risk group. Conclusion: We constructed a novel lung adenocarcinoma irlncRNA signature with promising prognostic value using the TCGA database, based on paired irlncRNAs and not relying on lncRNAs special expression levels.
- Open Access
- 1 April 2019
- Published by Wolters Kluwer Health in Medicine
- Vol. 98 (17) , e15215
Efficacy and safety of grain moxibustion in hemiplegia
Background: The increasing morbidity of stroke brings enormous social and economic pressure to the countries. Hemiplegia is the common sequela of stroke patients, which affects their physical activities and daily life, and its optimal treatment is still an urgent problem. In Asian countries, moxibustion therapy is widely combined with rehabilitation in poststroke hemiplegia. Among them, grain moxibustion, due to its concentration on stimulating the acupoints and deep heat penetration, can promote neurorehabilitation after stroke. Therefore, based on the current literatures, the effectiveness and safety of grain moxibustion were systematically evaluated to provide possible alternative therapy for the rehabilitation of hemiplegia. Methods: Studies search for eligible randomized controlled trials (RCTs) that use grain moxibustion as the sole treatment for hemiplegia and their data extraction will be done by two researchers. Mean difference (MD) or relative risk (RR) with fixed or random effect model in terms of 95% confidence interval (CI) will be adopted for the data synthesis. To evaluate the risk of bias, the Cochrane's risk of bias assessment tool will be utilized. The sensitivity or subgroup analysis will also be conducted when meeting high heterogeneity (I 2 > 50%). Results: This meta-analysis will provide an authentic synthesis of the grain moxibustion's effect for hemiplegia. Conclusion: The findings of the review offer updated evidence and identify whether grain moxibustion can be an effective treatment for hemiplegia. PROSPERO registration number: PROSPERO CRD 42018117765
- 1 April 2019
- Published by Wolters Kluwer Health in Medicine
- Vol. 98 (17) , e15215
Open AccessEfficacy and safety of grain moxibustion in hemiplegia
Background: The increasing morbidity of stroke brings enormous social and economic pressure to the countries. Hemiplegia is the common sequela of stroke patients, which affects their physical activities and daily life, and its optimal treatment is still an urgent problem. In Asian countries, moxibustion therapy is widely combined with rehabilitation in poststroke hemiplegia. Among them, grain moxibustion, due to its concentration on stimulating the acupoints and deep heat penetration, can promote neurorehabilitation after stroke. Therefore, based on the current literatures, the effectiveness and safety of grain moxibustion were systematically evaluated to provide possible alternative therapy for the rehabilitation of hemiplegia. Methods: Studies search for eligible randomized controlled trials (RCTs) that use grain moxibustion as the sole treatment for hemiplegia and their data extraction will be done by two researchers. Mean difference (MD) or relative risk (RR) with fixed or random effect model in terms of 95% confidence interval (CI) will be adopted for the data synthesis. To evaluate the risk of bias, the Cochrane's risk of bias assessment tool will be utilized. The sensitivity or subgroup analysis will also be conducted when meeting high heterogeneity (I 2 > 50%). Results: This meta-analysis will provide an authentic synthesis of the grain moxibustion's effect for hemiplegia. Conclusion: The findings of the review offer updated evidence and identify whether grain moxibustion can be an effective treatment for hemiplegia. PROSPERO registration number: PROSPERO CRD 42018117765
- Open Access
- 1 February 2019
- Published by Wolters Kluwer Health in Medicine
- Vol. 98 (8) , e13936
Efficacy and safety of Zuogui Pill in treating osteoporosis
Background: Osteoporosis (OP) is a common skeletal disorder worldwide, resulting in increased bone fragility and high risk of fractures. The Zuogui Pill (ZGP), a classic Chinese herbal formulation, has played a vital role in the clinical practice of OP in China for centuries. Increasing studies have been performed for clarifying its anti-osteoporotic mechanisms. However, this treatment still lacks a systematic review for its efficacy and safety in the treatment of OP. Methods: Eight electronic databases will be searched from inception to November 2018 by 2 independent researchers, in order to collect qualified randomized controlled trials (RCTs) on the ZGP treatment for OP. The therapeutic effects according to bone mineral density (BMD) will be adopted as the primary outcomes. RevMan V.5.3 software will be used for the data synthesis and the Cochrane's risk of bias assessment tool will be used to assess the risk of bias. Results: This review will conduct a high-quality synthesis on present evidence of ZGP for OP. Conclusion: The conclusion of the study will indicate whether ZGP is an effective treatment for OP by providing updated evidence. PROSPERO registration number: PROSPERO CRD 42018114366
- 1 February 2019
- Published by Wolters Kluwer Health in Medicine
- Vol. 98 (8) , e13936
Open AccessEfficacy and safety of Zuogui Pill in treating osteoporosis
Background: Osteoporosis (OP) is a common skeletal disorder worldwide, resulting in increased bone fragility and high risk of fractures. The Zuogui Pill (ZGP), a classic Chinese herbal formulation, has played a vital role in the clinical practice of OP in China for centuries. Increasing studies have been performed for clarifying its anti-osteoporotic mechanisms. However, this treatment still lacks a systematic review for its efficacy and safety in the treatment of OP. Methods: Eight electronic databases will be searched from inception to November 2018 by 2 independent researchers, in order to collect qualified randomized controlled trials (RCTs) on the ZGP treatment for OP. The therapeutic effects according to bone mineral density (BMD) will be adopted as the primary outcomes. RevMan V.5.3 software will be used for the data synthesis and the Cochrane's risk of bias assessment tool will be used to assess the risk of bias. Results: This review will conduct a high-quality synthesis on present evidence of ZGP for OP. Conclusion: The conclusion of the study will indicate whether ZGP is an effective treatment for OP by providing updated evidence. PROSPERO registration number: PROSPERO CRD 42018114366